998 results match your criteria: "Texas Children's Cancer Center[Affiliation]"
Int J Mol Sci
March 2023
Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030-4009, USA.
DNA damage response (DNADR) recognition and repair (DDR) pathways affect carcinogenesis and therapy responsiveness in cancers, including leukemia. We measured protein expression levels of 16 DNADR and DDR proteins using the Reverse Phase Protein Array methodology in acute myeloid (AML) ( = 1310), T-cell acute lymphoblastic leukemia (T-ALL) ( = 361) and chronic lymphocytic leukemia (CLL) ( = 795) cases. Clustering analysis identified five protein expression clusters; three were unique compared to normal CD34+ cells.
View Article and Find Full Text PDFLeukemia
June 2023
Department of Pediatrics and the Center for Childhood Cancer Research, the Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Pediatr Blood Cancer
June 2023
Department of Pediatric and Adolescent Medicine, Mayo Clinic and Foundation, Rochester, Minnesota, USA.
Background: To determine outcomes of children with rhabdomyosarcoma (RMS) with isolated lung metastases.
Methods: Data were analyzed for 428 patients with metastatic RMS treated on COG protocols. Categorical variables were compared using Chi-square or Fisher's exact tests.
Surg Neurol Int
February 2023
Department of Neurosurgery, Baylor College of Medicine/Texas Children's Hospital, Houston, United States.
Background: Gangliogliomas (GGs) are rare tumors of the central nervous system composed of neoplastic neural and glial cells and are typically low-grade. Intramedullary spinal anaplastic GGs (AGG) are rare, poorly understood, and often aggressive tumors that can result in widespread progression along the craniospinal axis. Due to the rarity of these tumors, data are lacking to guide clinical and pathologic diagnosis and standard of care treatment.
View Article and Find Full Text PDFHaematologica
October 2023
Division of Oncology and the Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA, USA; Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
Front Oncol
February 2023
Pediatric Cancer Biology, Children's Cancer Therapy Development Institute, Beaverton, OR, United States.
Background & Aims: Hepatocytic cells found during prenatal development have unique features compared to their adult counterparts, and are believed to be the precursors of pediatric hepatoblastoma. The cell-surface phenotype of hepatoblasts and hepatoblastoma cell lines was evaluated to discover new markers of these cells and gain insight into the development of hepatocytic cells and the phenotypes and origins of hepatoblastoma.
Methods: Human midgestation livers and four pediatric hepatoblastoma cell lines were screened using flow cytometry.
Cancers (Basel)
February 2023
Department of Pediatric Hematology/Oncology, Texas Children's Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA.
Survival of pediatric AML remains poor despite maximized myelosuppressive therapy. The (PJP)-treating medication atovaquone (AQ) suppresses oxidative phosphorylation (OXPHOS) and reduces AML burden in patient-derived xenograft (PDX) mouse models, making it an ideal concomitant AML therapy. Poor palatability and limited product formulations have historically limited routine use of AQ in pediatric AML patients.
View Article and Find Full Text PDFLeukemia
May 2023
Texas Children's Cancer Center, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA.
J Neurosurg Pediatr
May 2023
2Department of Pediatrics, Texas Children's Cancer Center, Texas Children's Hospital, Baylor College of Medicine, Houston.
J Surg Oncol
April 2023
Department of Orthopaedics, James Cancer Hospital and Nationwide Children's Hospital, Columbus, Ohio, USA.
Background And Objectives: The impact upon wound healing of targeted molecular therapies, when incorporated into neoadjuvant therapy of soft tissue sarcoma, is largely unknown. Here, we describe wound complications following addition of pazopanib, a tyrosine kinase inhibitor (TKI), to neoadjuvant radiotherapy (RT) +/- chemotherapy for soft tissue sarcoma.
Methods: Wound complications were evaluated on dose-finding and randomized arms of ARST1321, a phase II/III study incorporating neoadjuvant RT, +/- pazopanib, +/- ifosfamide/doxorubicin (ID) for sarcoma therapy.
bioRxiv
January 2023
Department of Pediatrics, Division of Hematology/Oncology, Baylor College of Medicine, Houston, TX 77030, USA.
Telomere length maintenance is crucial to cancer cell immortality. Up to 15% of cancers utilize a telomerase-independent, recombination-based mechanism termed alternative lengthening of telomeres (ALT). The primary ALT biomarker is the C-circle, a type of circular DNA with extrachromosomal telomere repeats (cECTRs).
View Article and Find Full Text PDFBlood Adv
November 2023
Division of Hematology/Oncology, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada.
Children with Down syndrome (DS) are at a significantly higher risk of developing acute myeloid leukemia, also termed myeloid leukemia associated with DS (ML-DS). In contrast to the highly favorable prognosis of primary ML-DS, the limited data that are available for children who relapse or who have refractory ML-DS (r/r ML-DS) suggest a dismal prognosis. There are few clinical trials and no standardized treatment approach for this population.
View Article and Find Full Text PDFLancet Oncol
February 2023
Pediatric Hematology-Oncology, IWK Health Centre, Dalhousie University, Halifax, NS, Canada.
Purpose: Novel biomarkers are needed to differentiate outcomes in intermediate-risk rhabdomyosarcoma (IR RMS). We sought to evaluate strategies for identifying circulating tumor DNA (ctDNA) in IR RMS and to determine whether ctDNA detection before therapy is associated with outcome.
Patients And Methods: Pretreatment serum and tumor samples were available from 124 patients with newly diagnosed IR RMS from the Children's Oncology Group biorepository, including 75 patients with fusion-negative rhabdomyosarcoma (FN-RMS) and 49 with fusion-positive rhabdomyosarcoma (FP-RMS) disease.
Accurate assessment of treatment response and residual disease is indispensable for the evaluation of cancer treatment efficacy. However, performing tissue biopsies for longitudinal follow-up poses a major challenge in the management of solid tumours like neuroblastoma. In the present study, we evaluated whether circulating miRNAs are suitable to monitor neuroblastoma tumour burden and whether treatment-induced changes of miRNA abundance in the tumour are detectable in serum.
View Article and Find Full Text PDFPediatr Blood Cancer
March 2023
Pediatric Oncology Unit, Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Mol Ther
March 2023
Department of Internal Medicine, Saint Louis University, St. Louis, MO 63104, USA; Department of Molecular Microbiology & Immunology and Saint Louis University, St. Louis, MO 63104, USA. Electronic address:
Overexpression of Lin28 is detected in various cancers with involvement in the self-renewal process and cancer stem cell generation. In the present study, we evaluated how the Lin28 axis plays an immune-protective role for tumor-initiating cancer cells in hepatocellular carcinoma (HCC). Our result using HCC patient samples showed a positive correlation between indoleamine 2,3-dioxygenase-1 (IDO1), a kynurenine-producing enzyme with effects on tumor immune escape, and Lin28B.
View Article and Find Full Text PDFJ Adolesc Young Adult Oncol
October 2023
Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston, Texas, USA.
With increased use of genomic testing in cancer research and clinical care, it is important to understand the perspectives and decision-making preferences of adolescents and young adults (AYAs) with cancer and their treating oncologists. We conducted an interview substudy of the BASIC3 Study, which enrolled newly diagnosed cancer patients <18 years of age with assent. Of 32 young adults (YAs) with cancer who reached the age of majority (AOM; 18 years) while on study, 12 were successfully approached and all consented to study continuation at AOM.
View Article and Find Full Text PDFNat Commun
December 2022
Pre-clinical Neuro-oncology Research Program, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, 77030, USA.
Eur J Hum Genet
April 2023
Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston, TX, USA.
Nucleic Acids Res
January 2023
McDonnell Genome Institute, Washington University in St Louis School of Medicine, St. Louis, MO, USA.
Clin Cancer Res
January 2023
Genetics Branch, NCI, NIH, Bethesda, Maryland.
Leuk Lymphoma
February 2023
Department of Pathology & Immunology, Baylor College of Medicine, Houston, TX, USA.
Nat Commun
November 2022
Pre-clinical Neuro-oncology Research Program, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, 77030, USA.